Assuming continued positive results of clinical trials and regulatory
approval, Axcan 's product candidates approaching commercialization are:

<<
---------------------- ---------------------------------------------------
Product Candidate Indication Estimated Launch Date
------------------------------------------------------------------- ------
HELIZIDE Eradication of - Second half, fiscal 2006
Helicobacter
pylori bacterium
-------------------- -----------------------------------------------------
CANASA (rectal gel) Treatment of Distal - Second half, fiscal 2006
Ulcerative Colitis
-------------- -----------------------------------------------------------
ITAX Treatment of - First half, fiscal 2007
Functional Dyspepsia

Treatment of - Fiscal 2008
Diabetic Gastroparesis
-------------------------------------------------------------------------
HEPENAX Treatment of - Second half, fiscal 2008
Porto-Systemic
Encephalopathy
------------------------------------------------- ------------------------
PHOTOFRIN Treatment of - Phase III to start during
Cholangiocarcinoma second quarter 2005

- Launch date to be
determined
-------------------------------------------------------------------------
>>

ABOUT AXCAN PHARMA

Axcan is a leading specialty pharmaceutical company involved in the field
of gastroenterology. Actual results could differ
materially from those projected herein and depend on a number of factors,
including, but not limited to, the successful and timely completion of
clinical studies, the difficulty of predicting FDA and other regulatory
approvals, the commercialization of a drug or therapy after regulatory
approval is received, acceptance and demand for new pharmaceutical
products, the impact of competitive products and pricing, new product
development and launch, reliance on key strategic alliances, availability
of raw materials, the regulatory environment, fluctuations in our
operating results, the protection of our intellectual property and other
risks detailed from time to time in the Company 's filings with the
Securities and Exchange Commission and under the Canadian Securities
Commissions.

This will direct you to other important categories.

mucopolysaccharidose dysplasias

Consensus on Childhood Obesity Recommends Classification as Disease

Approximately 14-15 percent of all 15-year-olds in the
United States can be classified as obese. These may include
diabetes, metabolic syndrome, hyperandrogenism (hormomal perturbations place
the obese adolescent girl at a high risk of menstrual disorders and early
onset of polycystic ovarian syndrome), heart disease, hypertension,
respiratory factors and sleep disorders , among many others. The Endocrine Society
is based in Chevy Chase, Maryland.

Annual General Meeting of Shareholders - Axcan Prepares for a New Era of Growth - Advances ITAX Development Program and Launch Strategy

Here you will find many resourceful links to sites providing information, resources and support to parents and families of children with special needs.

individualised cerebral

17 - During the
Axcan Pharma Inc.

"Safe Harbor" statement under the Private Securities Litigation Reform
Act of 1995.

cystic individualised

The
consensus statement reflects the conclusions from an international summit held
in Israel last year and includes a controversial recommendation to classify
obesity as a disease.

JCE+M is one of four journals published by The Endocrine Society.

utilize prematurity

The U. To learn more about the Society , and the
field of endocrinology, visit the Society's web site at
http://www.ObesityInAmerica.org or contact
media@endo-society. Its common shares are listed on the Toronto Stock Exchange under the
symbol "AXP" and on the NASDAQ National Market under the symbol "AXCA".

scoliosis skeletal

Consensus Statement Reflecting Israel Summit of 65 Physicians,
Endocrinologists and Health Professionals Published in The
Journal of Clinical Endocrinology + Metabolism

CHEVY CHASE, Md .
"Beyond the year 2007, I strongly believe that Axcan will be able to
launch innovative products at an average rate of one per year for each of the
following five years," said Mr. and
its subsidiaries.

If you can not find what you are looking for, please contact one of our editors and we will be happy to assist you.

behavioural givers

"
Mr.

behavioural mucopolysaccharidose

"Our goal is to emphasize the safest means for primary care physicians to
manage obese patients," says Dr. Leon F.

This release contains forward -looking statements, which reflect the
Company's current expectations regarding future events .

behavioural tracheostomy

fetal scoliosis

"These recommendations should provide incentive for
the public and private sectors to mobilize resources to stem the tide of
increasing body mass in children and adults.

tracheostomy utilize

S. Including
the classification of obesity as a disease in the recommendations is a
critical part of helping the medical community better evaluate and determine
the best treatment for obese children and lessen their health risks as they
grow older."

neurodevelopmental individualised

Researchers have found that children who are obese have a
higher risk for adult obesity, which is strongly associated with many serious
medical complications that impair quality of life and lead to additional
increased health risks. With health care costs of patients whose body mass index
(BMI) is greater than 35 reaching 44 percent more than those of non -obese
patients, the need for a consensus among physicians and health professionals
is necessary .org to order a complimentary copy of "The Endocrine Society
Weighs In - A Handbook on Obesity In America. TSX SYMBOL (Toronto Stock Exchange): AXP
NASDAQ SYMBOL (NASDAQ National Market ): AXCA

MONT-SAINT-HILAIRE, Quebec, Feb.

pancreas palsy

Obese children
are also at greater risk of anxiety and depression.
Gosselin, announced a new era of growth for Axcan citing as key factors, the
expansion of the Company's product pipeline during the last five years,
including the potential "blockbuster" drug, ITAX (itopride hydrochloride) for
the treatment of functional dyspepsia, and a 9% to 11% increase in the fiscal
2005 research and development budget.
Apart from the Company 's present portfolio and pipeline of products,
shareholders also learned that Axcan is well positioned to pursue strategic,
accretive acquisitions with $70 million in annual cash flow, $40 million in
cash and cash equivalents and a $125-million unused credit facility.

behavioural givers

Axcan's products are marketed by its own sales force in North America and
Europe. To the extent any
statements made in this release contain information that is not
historical, these statements are essentially forward looking and are
often identified by words such as "anticipate," "expect," "estimate,"
"intend," "project," "plan" and "believe.

mucopolysaccharidose neurodevelopmental

Founded
in 1916, The Endocrine Society is the world's oldest , largest, and most active
organization devoted to research on hormones, and the clinical practice of
endocrinology.7 million (all dollar amounts
stated in US dollars). Axcan markets a broad line of prescription products sold
for the treatment of symptoms in a number of gastrointestinal diseases and
disorders such as inflammatory bowel disease, irritable bowel syndrome,
cholestatic liver diseases and complications related to cystic fibrosis." Forward-looking statements are
subject to risks and uncertainties. The Company disclaims any obligation to update these
forward-looking statements. The reader is cautioned not to rely on these
forward-looking statements.

tracheostomy givers

Gosselin pointed out that ITAX alone could "more than double" Axcan's
revenues.

pancreas tracheostomy

fetal fibrosis

This landmark statement reviews the available research
evidence on the diagnosis, prevalence, causes (including endocrine disorders ),
risks, prevention and treatment of childhood obesity. The statement notes that, between
the years 1980 and 2000, the prevalence of overweight children doubled among
children aged six to 11 and tripled among those aged 12-17."
By classifying obesity as a legitimate disease, the consensus statement
paves the way for public funding and insurer's reimbursement for obesity
treatment programs and spurring further research to more effectively prevent
and treat obesity. Endocrinologists are specially trained doctors who diagnose,
treat and conduct basic and clinical research on complex hormonal disorders
such as diabetes, thyroid disease, osteoporosis, obesity, hypertension,
cholesterol and reproductive disorders.6 million with net income of $48. "That is why we believe that a
substantial increase in our research and development budget for fiscal 2005 is
necessary to take full advantage of the multiple new product launch
opportunities that the future holds for Axcan, including ITAX , which could be
the biggest product in Axcan's history. Axcan's core business, always geared
towards gastroenterology, revolves around five therapeutic areas: diseases of
the liver, the pancreas, the bowel, gastrointestinal (GI) and GI-related
cancers and other gastrointestinal disorders.

The names ITAX, Salofalk, Helizide, Hepenax, Photofrin and Canasa
appearing in this press release are trademarks of Axcan Pharma Inc.

congenital fetal

, A consensus statement on
childhood obesity was published today in The Journal of Clinical Endocrinology
+ Metabolism, one of the four journals of The Endocrine Society. ("Axcan" or the "Company") annual shareholders' meeting held
today in Montreal, President and Chief Executive Officer, Mr.

Special Needs in this category is being defined as anything related to developmental disorders and or developmental delays.

If you are looking for other sites concerning learning disabilities, behavioral disabilities or other childhood disorders, please utilize the 'at links' listed at the top of the page.

premature mucopolysaccharidose

These recommendations not only provide a platform for future
corrective action but encourage early intervention at the onset of obesity.
Without proper intervention, serious health risks will likely begin to
appear in obese adolescents and children as they grow older. Gosselin.

individualised behavioural

org

To learn how The Endocrine Society is combating obesity and its related
conditions visit http://www. Total revenues for the Company in fiscal
2004 were $243.

You may like to use the 'see also' categories in your search.

palsy fetal

Henry Anhalt, a participant of the Obesity
Consensus Working Group and physician at Saint Barnabas Medical Center in
Livingston , New Jersey.

Welcome to the Health/Child Health/Special Needs category of the Open Directory Project .

neurodevelopmental premature

The following is a partial list of recommendations in the statement that
can be implemented by parents, schools, healthcare providers and government
and regulatory agencies to help prevent the onset of childhood obesity:

* Normalize the mother's body mass index prior to pregnancy
* Maintain moderate exercise during pregnancy
* Breast feed for up to three months
* Eat meals as a family in a fixed place and time
* Do not skip meals, especially breakfast
* Use small dishes and keep serving dishes away from the table
* Eliminate school fundraisers with candy and cookie sales
* Install water fountains in schools
* Give age-appropriate expectations for body weight in children
* Classify obesity as a legitimate disease for treatment and insurance
purposes
* Make exercise programs tax deductible

The statement also includes evidence from previous findings that have
shown the adverse impact obesity has on existing endocrine and metabolic
disorders such as cardiovascular risk, diabetes and hypertension.

scoliosis palsy

Pediatric obesity is now recognized as a major medical and health problem
all over the world. ranked
among the highest of 15 countries in the study in terms of prevalence of
overweight and obese boys and girls. Today, The Endocrine Society's
membership consists of over 12,000 scientists, physicians , educators, nurses
and students, in more than 80 countries. Together, these members represent all
basic, applied, and clinical interests in endocrinology.

fetal pancreas

endo-society. The Company has built a strong multi-product gastrointestinal base
focusing on unmet therapeutic needs.

mucopolysaccharidose fetal

---

- - kjjkjk

Loading...

(Note: These pages use the Atlas Content Safeguard System (ACSS) and require that Javascript is enabled for viewing.)